What is multiple sclerosis?

Multiple sclerosis is an autoimmune condition where the immune system attacks the myelin coating of nerves in the brain and spinal cord — causing vision problems, numbness, weakness, balance issues, and fatigue in episodes or progressively. Most common neurological disease in young adults — diagnosis typically 20s to 40s. MRI and neurology assessment confirm. Disease-modifying drugs reduce relapses — no cure yet but outcomes improving. See a GP urgently for sudden vision loss in one eye or new neurological symptoms lasting over 24 hours.

What are the first signs of MS?

Optic neuritis — blurred or painful vision one eye; numbness or tingling limbs or face; weakness; balance problems; Lhermitte sign — electric shock down spine on neck flexion; fatigue; bladder urgency. Symptoms often develop over days, last weeks, then improve partially — disseminated in time and space.

What causes multiple sclerosis?

Autoimmune demyelination — exact trigger unknown — combination of genetic susceptibility and environmental factors (low vitamin D, EBV infection, smoking). Not contagious. More common further from equator — latitude gradient in incidence.

Is there a cure for MS?

No cure currently — disease-modifying treatments reduce relapses and slow progression especially relapsing forms. Stem cell transplantation (HSCT) for highly active MS in specialist centres. Symptomatic treatments — fatigue management, spasticity drugs, bladder care. Research active globally.

What is the difference between relapsing and progressive MS?

Relapsing-remitting (RRMS) — clear attacks with recovery — 85% at onset. Secondary progressive — gradual worsening after years of relapses. Primary progressive (PPMS) — steady decline from start without distinct relapses — harder to treat, ocrelizumab approved.

Does MS affect life expectancy?

Slightly reduced on average — gap narrowing with modern DMTs — most live near-normal lifespan. Complications — mobility impairment, infections. Quality of life highly variable — many remain working with support and treatment.

Multiple sclerosis: Symptoms & Treatment

Multiple sclerosis — immune attack on myelin

Multiple sclerosis (MS) is chronic autoimmune demyelination of central nervous system (brain + spinal cord) — disrupted nerve conduction → variable neurological symptoms.

Most common disabling neurological disease of young adults — UK ~130,000.

Peak onset 20s–40s — not childhood rare, diagnosis later life possible.

How MS presents

Relapsing-remitting pattern:

new symptoms over days
plateau then partial recovery over weeks–months
attacks separated in time, ** lesions separated in space**

Common symptoms:

optic neuritis — painful monocular vision loss
sensory — numbness, pins and needles, band-like torso
motor — weakness, spasticity
coordination — ataxia, tremor
brainstem — diplopia, facial weakness
fatigue — most disabling symptom many
bladder/bowel — urgency, retention
cognitive — processing speed

Progressive forms:

SPMS — gradual decline after RRMS
PPMS — progression from onset — 10–15%

Diagnosis

McDonald criteria — MRI + clinical

MRI brain/spine:

periventricular, juxtacortical, infratentorial, spinal T2/FLAIR lesions
** Dawson fingers**
gadolinium enhancement — active inflammation

LP — oligoclonal bands — supportive

Exclude mimics:

NMOSD — aquaporin-4 antibody
MOGAD
SLE, Sjögren, sarcoid
vitamin B12 deficiency

Treatment

Relapse

High-dose IV methylprednisolone — 3–5 days — speeds recovery, doesn’t alter long-term disability

Disease-modifying therapies (DMTs)

Reduce relapse rate, MRI activity, disability progression:

Efficacy tier	Examples
Moderate	dimethyl fumarate, teriflunomide, fingolimod
High	ocrelizumab, natalizumab, alemtuzumab, cladribine

Choice — activity, prognosis, family planning, JCV status (PML risk with natalizumab)

PPMS

Ocrelizumab — only licensed DMT with PPMS evidence

Symptoms

fatigue — exercise, modafinil selected
spasticity — baclofen
neuropathic pain — gabapentin
bladder — oxybutynin, intermittent self-catheterisation

Living with MS

MS Society — support, benefits advice

Heat sensitivity — Uhthoff — cooling strategies

Vitamin D — maintain sufficiency

Smoking cessation — accelerates progression

Pregnancy — often reduced relapse third trimester, rebound postpartum — plan with neurologist

MS is unpredictable not untreatable — early neurology, DMT, symptom management preserve life trajectory.

Common questions about multiple sclerosis

What are the first signs of MS?: Optic neuritis — blurred or painful vision one eye; numbness or tingling limbs or face; weakness; balance problems; Lhermitte sign — electric shock down spine on neck flexion; fatigue; bladder urgency. Symptoms often develop over days, last weeks, then improve partially — disseminated in time and space.
What causes multiple sclerosis?: Autoimmune demyelination — exact trigger unknown — combination of genetic susceptibility and environmental factors (low vitamin D, EBV infection, smoking). Not contagious. More common further from equator — latitude gradient in incidence.
Is there a cure for MS?: No cure currently — disease-modifying treatments reduce relapses and slow progression especially relapsing forms. Stem cell transplantation (HSCT) for highly active MS in specialist centres. Symptomatic treatments — fatigue management, spasticity drugs, bladder care. Research active globally.
What is the difference between relapsing and progressive MS?: Relapsing-remitting (RRMS) — clear attacks with recovery — 85% at onset. Secondary progressive — gradual worsening after years of relapses. Primary progressive (PPMS) — steady decline from start without distinct relapses — harder to treat, ocrelizumab approved.
Does MS affect life expectancy?: Slightly reduced on average — gap narrowing with modern DMTs — most live near-normal lifespan. Complications — mobility impairment, infections. Quality of life highly variable — many remain working with support and treatment.

Sources

How we reviewed this page

Medically reviewed by the HealthAnswers UK doctor review panel

First published: 14 June 2026
Medically reviewed: 3 July 2026
Next review due: 3 July 2029 or sooner if NHS or NICE guidance changes

Written by HealthAnswers editorial team. Published by HealthAnswers (Elite Digital AI Solutions Ltd). How we review content · Report a problem with this page